Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.68 |
| ▸ | CA2 | P00918 | 14/20 | 0.68 |
| ▸ | CA9 | Q16790 | 14/20 | 0.68 |
| ▸ | CA12 | O43570 | 6/20 | 0.68 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14754541 | 0.92 | CA1 (0.67) | CA1CA2CA9CA12CA14 | |
| SCHEMBL24444501 | 0.91 | CA9 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL17245254 | 0.90 | CA1 (0.64) | CA1CA2CA9CA12CA14 | |
| SCHEMBL19455756 | 0.90 | CA1 (0.64) | CA1CA2CA9CA12CA14 | |
| SCHEMBL26084225 | 0.88 | CA1 (0.68) | CA1CA2CA9CA12CA14 | |
| SCHEMBL14642801 | 0.88 | CA1 (0.67) | CA1CA2CA9CA12CA14 | |
| SCHEMBL16525362 | 0.87 | CA1 (0.64) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21728989 | 0.86 | CA9 (0.73) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21151146 | 0.86 | CA9 (0.73) | CA1CA2CA9CA12CA14 | |
| SCHEMBL5057133 | 0.86 | CA9 (0.64) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11815517-B2 | Antibodies to 25-hydroxyvitamin D2 and D3 | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210055314-A1 | METHOD FOR DETECTING TOTAL 25-HYDROXYVITAMIN D USING ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11815517-B2 | Antibodies to 25-hydroxyvitamin D2 and D3 | VDR, GC, CYP24A1 | CA1 1616/4885CA2 1047/4885CA9 2331/4885 |
| US-20210055314-A1 | METHOD FOR DETECTING TOTAL 25-HYDROXYVITAMIN D USING ANTIBODIES TO 25-HYDROXYVITAMIN D2 AND D3 | GC, VDR, CYP24A1 | CA1 1785/4885CA2 929/4885CA9 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.